(MENAFN- IANS) New Delhi, Nov 22 (IANS) The Pune based vaccines manufacturer Serum Institute of India (SII) has got the nod to export Covid vaccines under the COVAX programme, said a source on Monday.
The ministry has allowed SII to export 50 lakh doses of COVID-19 vaccine Covishield to the COVAX, an UN Global body.
COVAX is co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organization that aims to accelerate the development and manufacture of Covid vaccines. Covax facility was created to ensure global equitable access to Covid-19 vaccines after the outbreak of Covid pandemic.
The first batch of the vaccines will be exported to Nepal, Tajikistan and Mozambique, official sources said. The SII will also export Covishield to Bangladesh under COVAX. The Serum Institute can begin the vaccine export from November 23.
Union Health Minister Mansukh Mandaviya had announced that India will be resuming export of vaccines under Vaccine Maitri in the fourth quarter starting from October. He had said that vaccine export will resume to fulfill the commitment of India towards COVAX in line with the motto 'Vasudhaiva Kutumbakam'.
India stopped the Covid-19 vaccines in April this year after a severe surge in Covid case during the second wave to jab its own population. However, prior to the export ban, India had either sold or donated 66 million doses to nearly 100 countries. While announcing to resume the vaccine exports under Vaccine Maitri program, the Health Minister said that the surplus supply of vaccines will be used to fulfill the commitment towards the world for the collective fight against Covid-19.
While India has achieved 82 per cent vaccination coverage for the first dose, the second vaccine coverage remains under 60 per cent.
Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.